Wong-Beringer A - Search Results

1

Prevalence of the carbapenem-heteroresistant phenotype among ESBL-producing Escherichia coli and Klebsiella pneumoniae clinical isolates.

Tan K, Nguyen J, Nguyen K, Huse HK, Nieberg PH, Wong-Beringer A. Tan K, et al. J Antimicrob Chemother. 2020 Jun 1;75(6):1506-1512. doi: 10.1093/jac/dkaa048. J Antimicrob Chemother. 2020. PMID: 32181802

2

Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Wong-Beringer A. Wong-Beringer A. Pharmacotherapy. 2001 May;21(5):583-92. doi: 10.1592/phco.21.6.583.34537. Pharmacotherapy. 2001. PMID: 11349747 Review.

3

Implementing a program for switching from i.v. to oral antimicrobial therapy.

Wong-Beringer A, Nguyen KH, Razeghi J. Wong-Beringer A, et al. Am J Health Syst Pharm. 2001 Jun 15;58(12):1146-9. doi: 10.1093/ajhp/58.12.1146. Am J Health Syst Pharm. 2001. PMID: 11449860

4

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.

Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, Quinn JP, Bush K. Wong-Beringer A, et al. Clin Infect Dis. 2002 Jan 15;34(2):135-46. doi: 10.1086/324742. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740699

5

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.

Kriengkauykiat J, Porter E, Lomovskaya O, Wong-Beringer A. Kriengkauykiat J, et al. Antimicrob Agents Chemother. 2005 Feb;49(2):565-70. doi: 10.1128/AAC.49.2.565-570.2005. Antimicrob Agents Chemother. 2005. PMID: 15673734 Free PMC article.

6

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.

Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Hsu DI, et al. J Antimicrob Chemother. 2005 Apr;55(4):535-41. doi: 10.1093/jac/dki026. Epub 2005 Feb 22. J Antimicrob Chemother. 2005. PMID: 15728150

7

Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.

Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A. Nguyen LH, et al. J Antimicrob Chemother. 2008 Mar;61(3):714-20. doi: 10.1093/jac/dkm510. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222951

8

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. Hsu DI, et al. Int J Antimicrob Agents. 2008 Nov;32(5):378-85. doi: 10.1016/j.ijantimicag.2008.05.007. Epub 2008 Aug 12. Int J Antimicrob Agents. 2008. PMID: 18701261

9

Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.

Yamaki J, Synold T, Wong-Beringer A. Yamaki J, et al. Antimicrob Agents Chemother. 2011 Sep;55(9):4432-5. doi: 10.1128/AAC.00122-11. Epub 2011 Jun 13. Antimicrob Agents Chemother. 2011. PMID: 21670179 Free PMC article.

10

Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.

Yamaki J, Synold T, Wong-Beringer A. Yamaki J, et al. Antimicrob Agents Chemother. 2013 Sep;57(9):4562-5. doi: 10.1128/AAC.00470-13. Epub 2013 Jul 1. Antimicrob Agents Chemother. 2013. PMID: 23817369 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters